Teduglutide (ALX-0600) is a glucagon-like peptide-2 analog that increases intestinal absorption by promoting mucosal growth and reducing mucosal degradation, improving intestinal recovery. It is used in the study of short bowel syndrome (SBS). Teduglutide activates NR4a1/nur77 expression and FXR signaling, alleviating intestinal dysfunction in mice and improving lung injury, making it useful for studying metabolic and cardiovascular diseases.

Teduglutide (2.5 μM, 36 h) can activate the expression of NR4a1/nur77 in human hepatic stellate cells. [1]
Teduglutide increased the proliferation and decreased apoptosis of all intestinal epithelial cells in the short intestinal neonatal piglet model. [2]

Liver inflammation, fibrosis, and reactive bile duct cell phenotypes were improved in Mdr2 mice treated with Teduglutide (intraperitoneal injection).
Teduglutide promotes Fxr-Fgf15/19 signaling in the gut, resulting in decreased Cyp7a1 and increased Cyp2c70 expression in the liver, contributing to the hepatoprotective and antifibrotic effects of GLP-2 in Mdr2-/- mouse models. [1]
Teduglutide (0.1 mg/kg/d) improved mucosal surface area and acute nutrient handling capacity of newborn piglets with ileojejunal resection. [2]